glofitamab,epcoritamab
abbvie,roche,genmab
['glofitamab', 'epcoritamab', 'lymsm', 'dlbcl']
promising results in r/r dlbcl setting 1) durable response in patients achieving cr after glofitamab treatment
2) epcoritamab + r-dhax/c: high response rate and excellent pfs
3)interesting data about car-t in primary &amp; secondary cns involvement #ash2022 #lymsm
Research Fellow @MSKCancerCenter Hematologist @hospitalclinic #Lymphoma #CLL.